Varian, Proxima team up for partial breast irradiation

AuntMinnie.com staff writers
Jul 6, 2004

Varian Medical Systems and Proxima Therapeutics have formed an alliance. Under the terms of the deal, Proxima of Alpharetta, GA, will become the exclusive distributor of the Palo Alto, CA-based vendor's MammoSource HDR brachytherapy afterloader.

MammoSource was developed specifically to work with Proxima's MammoSite device, which treats breast cancer with localized high-dose-rate brachytherapy, according to the firms. The afterloader will be available to treatment centers on a fee-for-use basis.

By AuntMinnie.com staff writers
July 7, 2004

Related Reading

Varian reports first clinical use of robotic imager, July 1, 2004

Varian plans stock split, June 14, 2004

Varian to sell MammoSite in Europe, May 26, 2004

Proxima touts MammoSite research, May 17, 2004

Varian grows Q2 sales and profit, April 29, 2004

Copyright © 2004 AuntMinnie.com

Latest in Breast
Medical Bill Final Notice
Removing patient fees for DBT improves utilization, but inequity remains
June 19, 2025
Clinical workflow with Clairity Breast. Graphic courtesy of Clairity.
Clairity deploys AI for breast cancer risk prediction
June 6, 2025
Korstjens Davin Thumbnail
IMV: Patient satisfaction tops mammography department priorities
June 5, 2025
Pxl 20250531 175048475~2
Mobile mammography units face diagnostic challenges
June 1, 2025
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2004 06 29 14 43 27 706
Breast
Honing MRI, PET/CT protocols for larger patients
2004 03 15 17 04 31 706
Breast
Computer assistance aids mammographers in making more specific diagnosis, avoiding biopsy
2004 02 23 06 53 38 706
Breast
Austrian study finds FFDM, CR equivalent for breast cancer detection
More in Breast
Removing patient fees for DBT improves utilization, but inequity remains
By Erik L. Ridley
In a recent study, eliminating out-of-pocket costs for DBT reduced, but did not eliminate, disparities in utilization.
June 19, 2025
Medical Bill Final Notice
Clairity deploys AI for breast cancer risk prediction
By Erik L. Ridley
Clairity believes that its new AI software can deliver improvements over traditional breast cancer risk-prediction models.
June 6, 2025
Clinical workflow with Clairity Breast. Graphic courtesy of Clairity.
IMV: Patient satisfaction tops mammography department priorities
By Davin Korstjens
Mammography departments' top priority is providing patient-centered care.
June 5, 2025
Korstjens Davin Thumbnail
Mobile mammography units face diagnostic challenges
By AuntMinnie.com staff writers
There are opportunities to improve the service provided by mobile mammography units, according to research presented at ASCO 2025 in Chicago.
June 1, 2025
Pxl 20250531 175048475~2
RamSoft to integrate Therapixel's MammoScreen
By AuntMinnie.com staff writers
Commercial partnership adds AI-based breast cancer screening software to RamSoft's platforms.
May 21, 2025
Business Partner Handshake Intelligence
Lunit hits 1M mammogram milestone a year after Volpara purchase
By AuntMinnie.com staff writers
Lunit has achieved the milestone of helping to screen more than 1 million annual mammograms in North America.
May 19, 2025
Lunit
ARRS: Breast RT doesn't impact presence of breast arterial calcifications
By Kate Madden Yee
May 2, 2025
Thumbnail 71 Year Old Patient With History Of Left Breast Invasive Lobular Carcinoma Mindul Thumbnail
ARRS: How to manage 'controversial' high-risk breast lesions
By Amerigo Allegretto
Managing high-risk breast lesions with no consensus can be tricky, but breast radiologists can navigate this area.
April 30, 2025
Amie Lee, MD, presented at ARRS 2025 on managing 'controversial' high-risk breast lesions diagnosed on core needle biopsy. This slide outlines how to manage pleomorphic lobular carcinoma in situ (LCIS) via surgical excision.
Preop MRI fails to deliver results for breast cancer subtype
Preoperative MRI didn't improve outcomes in women with HER2-positive and hormone receptor-negative breast cancer in a new study.
April 29, 2025
Images show a palpable mass in the left breast in a 55-year-old woman. (A) Mammography shows a 26-mm ill-defined mass with fine linear calcifications in the central portion of the left breast (arrows). (B) ultrasound shows a 23-mm hypoechoic mass with calcifications in the corresponding area accompanying palpability (between the arrows). (C) An axial, fat-saturated, contrast-enhanced T1-weighted MRI scan shows an 18-mm irregular heterogeneous enhancing mass in the left breast (arrows). After breast-conserving surgery, the final pathologic report confirmed a grade II estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–positive invasive ductal carcinoma. There was no lymphovascular invasion, and the resection margins were clear. The patient declined both adjuvant chemotherapy and radiation therapy due to psychologic distress. (D) 11 months later, surveillance ultrasound helped to detect a new 25-mm irregular hypoechoic mass at the 12-o’clock position in the left breast (arrows). A subsequent ultrasound-guided biopsy confirmed it as a recurrence of grade II invasive ductal carcinoma, maintaining the same receptor statuses. Images courtesy of the RSNA.
iCAD partners with Microsoft on mammography suite integration
By AuntMinnie.com staff writers
iCAD will collaborate with Microsoft on incorporating a set of its AI-driven mammography tools into Microsoft’s Precision Imaging Network.
April 29, 2025
Breast Mammo Computer
ARRS: 'Report Cards' reduce BIRADS 3 usage
By Maryam Payne
"Report cards” were found to reduce rates of BI-RADS 3 assessment use, according to an award-winning poster presentation at ARRS 2025.
April 28, 2025
Breast Specialist Ultrasound Exam 400
Mammo uptake among veterans on par with nonveterans
By Amerigo Allegretto
Female veterans are as likely to undergo screening mammography as nonveteran women.
April 25, 2025
Mammogram Patient
Page 1 of 572
Next Page